HRP20192345T1 - Medicinski tretmani na bazi anamorelina - Google Patents
Medicinski tretmani na bazi anamorelina Download PDFInfo
- Publication number
- HRP20192345T1 HRP20192345T1 HRP20192345TT HRP20192345T HRP20192345T1 HR P20192345 T1 HRP20192345 T1 HR P20192345T1 HR P20192345T T HRP20192345T T HR P20192345TT HR P20192345 T HRP20192345 T HR P20192345T HR P20192345 T1 HRP20192345 T1 HR P20192345T1
- Authority
- HR
- Croatia
- Prior art keywords
- anamorelin
- use according
- patient
- cachexia
- procedure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 | |
| PCT/US2015/047435 WO2016036598A1 (en) | 2014-09-04 | 2015-08-28 | Medical treatments based on anamorelin |
| EP15838548.4A EP3188599B1 (en) | 2014-09-04 | 2015-08-28 | Medical treatments based on anamorelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20192345T1 true HRP20192345T1 (hr) | 2020-03-20 |
Family
ID=55436476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192345TT HRP20192345T1 (hr) | 2014-09-04 | 2015-08-28 | Medicinski tretmani na bazi anamorelina |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| HUE046894T2 (hu) | 2014-09-04 | 2020-04-28 | Helsinn Healthcare Sa | Anamorelinen alapuló gyógyászati kezelések |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| US12226448B2 (en) | 2018-12-20 | 2025-02-18 | Société des Produits Nestlé S.A. | Peanut oral immunotherapy dosing schedule for missed doses |
| US11229673B2 (en) | 2019-05-10 | 2022-01-25 | Société des Produits Nestlé S.A. | Methods for improving the quality of life of a patient with a peanut allergy |
| CN115569119A (zh) | 2019-08-30 | 2023-01-06 | 赫尔森保健股份公司 | 具有改善稳定性的阿拉莫林片剂的生产方法 |
| CA3158632A1 (en) | 2019-10-24 | 2021-04-29 | Toray Industries, Inc. | Therapeutic or prophylactic agent for cachexia |
| JP2024534464A (ja) * | 2021-09-17 | 2024-09-20 | 小野薬品工業株式会社 | 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法 |
| WO2025004650A1 (ja) * | 2023-06-28 | 2025-01-02 | 日清オイリオグループ株式会社 | 中高年者の疲労感を軽減するための剤及び組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| EP1660117A2 (en) * | 2003-08-06 | 2006-05-31 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| KR20070010151A (ko) | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| EP1768976B1 (en) * | 2004-06-29 | 2017-04-26 | Helsinn Healthcare S.A. | Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| MX2009008561A (es) * | 2007-02-13 | 2010-01-15 | Helsinn Therapeutics Us Inc | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| CN104470524A (zh) * | 2012-05-25 | 2015-03-25 | 拉夸里亚创药株式会社 | 用于治疗胃酸缺乏症的生长激素释放肽受体激动剂 |
| HUE046894T2 (hu) | 2014-09-04 | 2020-04-28 | Helsinn Healthcare Sa | Anamorelinen alapuló gyógyászati kezelések |
-
2015
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 HR HRP20192345TT patent/HRP20192345T1/hr unknown
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active Active
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active Active
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active Active
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en not_active Ceased
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-02 PH PH12017500392A patent/PH12017500392B1/en unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192345T1 (hr) | Medicinski tretmani na bazi anamorelina | |
| DOP2019000308A (es) | Imidazopirimidinas diazabicíclicas sustituidas y su uso para el tratamiento de trastornos respiratorios | |
| MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| CL2019000129A1 (es) | Compuestos diazaheterobicíclicos sustituidos y su uso. | |
| EP3447491A3 (en) | Diagnosis and treatments relating to th2 inhibition | |
| HK1202776A1 (en) | Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy | |
| PH12018501903B1 (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA201591290A3 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| MX2024002360A (es) | Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales. | |
| JP2017526695A5 (cg-RX-API-DMAC7.html) | ||
| WO2013188210A3 (en) | Treatment of side effects associated with parkinson's disease treatments | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| HK1214752A1 (zh) | 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法 | |
| BR112016016880A2 (pt) | Combinação para tratar câncer e seu uso, kit, e composição farmacêutica | |
| MX2018007152A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. | |
| EA201591693A1 (ru) | Новые соединения, модулирующие контроль над дыханием, и способы их применения | |
| WO2018111795A3 (en) | Use of sgc stimulators for the treatment of esophageal motility disorders | |
| Gui et al. | C29 MUSCLES, EXERCISE ASSESSMENT, AND REHABILITATION: Effect Of Exercise Training On Cancer Cachexia In Lewis Lung Carcinoma (llc) Mouse Model | |
| CN204364185U (zh) | 一种矫正器 | |
| RU2012142070A (ru) | Способ восстановительного лечения больных хроническим панкреатитом у работников с вредными условиями труда | |
| Wei | Harnessing autophagy to potentiate the antitumor effects of the tyrosine kinase inhibitor cabozantinib in prostate cancer cells | |
| UA82436U (ru) | Способ реабилитации детей с экстрасистолической аритмией | |
| UA116484U (uk) | Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом |